🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Sj-subway, a Predictor for the Recurrence of High-risk Hormone Receptor-positive Breast That is Sensitive to Extended Endocrine Therapy

Recruitingn/aAges 18 Years - 70 YearsFemaleShengjing Hospital
NCT04476485 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Hormone receptor-positive breast cancer accounts for about 70% of all breast cancers. Extended endocrine therapy with aromatase inhibitor is the current main treatment for hormone receptor-positive breast cancer. However, previous studies have shown a long-lasting risk of the recurrence of hormone receptor-positive breast cancer at early stage, and disease recurrence is considered inevitable only depending on a 5-year of adjuvant endocrine therapy. Therefore, extended endocrine therapy is considered as a possible measure to reduce the risk of recurrence. Numerous clinical studies have focused on extended endocrine therapy in patients with specific types of breast cancer. In 2017, the National Comprehensive Cancer Network (NCCN) updated the recommends for extended endocrine therapy with aromatase inhibitor, where postmenopausal early-stage breast cancer patients wo have high risk factors

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * early-stage invasive breast cancer positive for estrogen receptor and / or progesterone receptor is pathologically confirmed; * patients who have completed standard endocrine therapy for 5 years without recurrence and metastasis; * 18-70 years old; * patients with one of the following six manifestations: KI67 ≥ 30%; tumor size \> 2 cm; positive lymph nodes; histological grade III; vascular cancer thrombus; HER-2 gene overexpression or amplification. Exclusion Criteria: * with a history of other malignancies; * patients who have severe abnormalities in important organs, such as the heart, liver, and kidney or who cannot be tolerant to extended treatment due to poor constitution; * patients with severe osteoporosis or dyslipidemia, or those who cannot tolerate endocrine therapy ; * patients who have participated in other clinical trials.
💊

What it tests

  • endocrine therapy
📍

Where

12 sites
Cancer Hospital Affiliated to Harbin Medical University
Harbin, China
The Second Hospital of Jilin University
Changchun, China
Dalian Municipal Central Hospital
Dalian, China
Panjin Liaohe Oilfield Gem Flower Hospital
Panjin, China
Shengjing Hospital affiliated to China Medical University
Shenyang, China
Shengjing Hospital of China Medical University
Shenyang, China
Shengjing Hospital of China Medical University
Shenyang, China
Shengjing Hospital of China Medical University
Shenyang, China

…and 4 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy